Supplementary Table S1 from A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

Tsang, Erica S.; Aggarwal, Rahul R.; Dhawan, Mallika S.; Bergsland, Emily K.; Alvarez, Edwin A.; Calabrese, Susan; Pacaud, Romain; Garcia, Jose; Fattah, Delaire; Thomas, Scott; Grabowsky, Jennifer; Moasser, Mark M.; Munster, Pamela N.

doi:10.1158/2767-9764.22545363.v1

Supplementary Table S1 from A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

journal contribution

posted on 2023-04-04, 01:43 authored by Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Emily K. Bergsland, Edwin A. Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mark M. Moasser, Pamela N. Munster

A) Rationale for study drug dose interruption or reduction; B) Rationale for cisplatin dose interruption or reduction; C) Cisplatin dose intensity, stratified by dose level

History

ARTICLE ABSTRACT

The PI3K inhibitor alpelisib has limited activity alone, but there is interest in combinations in platinum-resistant tumors. In this phase Ib study of alpelisib with cisplatin, the objective response rate measured 29% but adverse events limited dose intensity. These promising results provide rationale for studying combinations with better tolerated platinum agents.

Usage metrics

Keywords

Clinical Trial Results Phase I clinical trials Clinical-Stage Research Chemotherapy Combination chemotherapy Small Molecule Agents Platinum complexes Kinase inhibitors

Licence

CC BY

Supplementary Table S1 from A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports